NASDAQ:ALLR Allarity Therapeutics (ALLR) Stock Forecast, Price & News $0.26 0.00 (0.00%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$0.25▼$0.2750-Day Range$0.26▼$3.9652-Week Range$0.25▼$118.30Volume1.22 million shsAverage Volume2.06 million shsMarket Capitalization$5.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Allarity Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.46% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($30.58) to ($19.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.12 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Allarity Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.46% of the outstanding shares of Allarity Therapeutics have been sold short.Short Interest Ratio / Days to CoverAllarity Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allarity Therapeutics has recently increased by 180.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllarity Therapeutics does not currently pay a dividend.Dividend GrowthAllarity Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLR. Previous Next 2.5 News and Social Media Coverage News SentimentAllarity Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Allarity Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 18 people have searched for ALLR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows11 people have added Allarity Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.49% of the stock of Allarity Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 1.61% of the stock of Allarity Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allarity Therapeutics are expected to grow in the coming year, from ($30.58) to ($19.82) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Allarity Therapeutics (NASDAQ:ALLR) StockAllarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.Read More Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLR Stock News HeadlinesMay 30, 2023 | finance.yahoo.comFirst Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual MeetingMay 13, 2023 | americanbankingnews.comAllarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest UpdateJune 1, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>April 27, 2023 | finance.yahoo.comAllarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023April 20, 2023 | marketwatch.comAllarity Therapeutics Shares Tumble on Public Offering >ALLRApril 19, 2023 | finance.yahoo.comAllarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public OfferingApril 19, 2023 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Down 22% Today?April 18, 2023 | markets.businessinsider.comAllarity Soars In Morning TradeJune 1, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>April 17, 2023 | finanznachrichten.deAllarity Therapeutics, Inc.: This Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' TrialApril 17, 2023 | finance.yahoo.comALLR: Clinical UpdateApril 17, 2023 | finance.yahoo.comThis Combination Therapy Could Help Change Cancer Treatment - Take A Deeper Look Into Allarity Therapeutics' TrialApril 16, 2023 | americanbankingnews.comShort Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Decreases By 70.0%April 11, 2023 | finance.yahoo.comAbstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual MeetingApril 2, 2023 | benzinga.comShould You Sell Allarity Therapeutics Inc (ALLR) Stock Thursday Morning?March 31, 2023 | finance.yahoo.comALLR: March Clinical UpdateMarch 28, 2023 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical StudiesMarch 28, 2023 | msn.comAllarity stock dips amid enrollment woes pushing cancer trials data to year endMarch 28, 2023 | finance.yahoo.comAllarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical StudiesMarch 24, 2023 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Announces Reverse Stock Split of Common StockMarch 24, 2023 | finance.yahoo.comAllarity Therapeutics Announces Reverse Stock Split of Common StockMarch 20, 2023 | msn.comWhy Allarity Therapeutics Shares Are SoaringMarch 20, 2023 | finance.yahoo.comAllarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid TumorsFebruary 23, 2023 | uk.finance.yahoo.comAllarity Therapeutics, Inc. (ALLR)February 8, 2023 | finance.yahoo.com6 F-Rated Penny Stocks Not Worth Your DimeJanuary 26, 2023 | seekingalpha.comALLR Allarity Therapeutics, Inc.January 23, 2023 | msn.comWhy Is Allarity Therapeutics (ALLR) Stock 72% Up Today?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLR Company Calendar Today5/31/2023Next Earnings (Estimated)10/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLR CUSIPN/A CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,053.89% Return on Assets-95.20% Debt Debt-to-Equity Ratio0.73 Current Ratio0.26 Quick Ratio0.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$2.61 per share Price / Cash Flow0.10 Book Value($0.16) per share Price / Book-1.63Miscellaneous Outstanding Shares19,140,000Free Float19,049,000Market Cap$4.99 million OptionableNot Optionable Beta-0.42 Key ExecutivesMr. James G. Cullem J.D. (Age 54)Interim CEO, Chief Bus. Officer, Sr. VP of Corp. Devel. & Director Comp: $356.85kDr. Marie Foegh DrSc (Age 79)M.D., Chief Medical Officer Comp: $424.08kMr. Peter Buhl Jensen Adj Professor (Age 68)M.D., M.D., Ph.D., Ph.D., Co-Founder Dr. Steen Meier Knudsen Ph.D. (Age 62)Founder & Chief Scientific Officer Mr. Thomas H. Jensen (Age 45)Founder, Sr. VP of Investor Relations & Director Mr. Claus Frisenberg Pedersen (Age 51)Chief Commercial Officer Ms. Joan Brown (Age 70)Interim CFO & Director of Financial Reporting Ms. Annie Rasmussen (Age 66)Chief of Clinical Operations More ExecutivesKey CompetitorsPainReformNASDAQ:PRFXOncorusNASDAQ:ONCRXenetic BiosciencesNASDAQ:XBIOArtelo BiosciencesNASDAQ:ARTLAptinyxNASDAQ:APTXView All Competitors ALLR Stock - Frequently Asked Questions Should I buy or sell Allarity Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allarity Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ALLR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLR, but not buy additional shares or sell existing shares. View ALLR analyst ratings or view top-rated stocks. How have ALLR shares performed in 2023? Allarity Therapeutics' stock was trading at $10.2830 at the beginning of 2023. Since then, ALLR stock has decreased by 97.5% and is now trading at $0.2607. View the best growth stocks for 2023 here. Are investors shorting Allarity Therapeutics? Allarity Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 470,800 shares, an increase of 180.4% from the April 30th total of 167,900 shares. Based on an average daily volume of 3,040,000 shares, the short-interest ratio is currently 0.2 days. View Allarity Therapeutics' Short Interest. When is Allarity Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, October 6th 2023. View our ALLR earnings forecast. When did Allarity Therapeutics' stock split? Allarity Therapeutics shares reverse split on Monday, March 27th 2023. The 1-35 reverse split was announced on Monday, March 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What is Allarity Therapeutics' stock symbol? Allarity Therapeutics trades on the NASDAQ under the ticker symbol "ALLR." How do I buy shares of Allarity Therapeutics? Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allarity Therapeutics' stock price today? One share of ALLR stock can currently be purchased for approximately $0.26. How much money does Allarity Therapeutics make? Allarity Therapeutics (NASDAQ:ALLR) has a market capitalization of $4.99 million. How can I contact Allarity Therapeutics? The official website for the company is www.allarity.com. The company can be reached via phone at 401-426-4664 or via email at investorrelations@allarity.com. This page (NASDAQ:ALLR) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.